Skip to content
2000
image of CD24 and Mutant p53: Emerging Therapeutic Targets in Prostate Cancer Progression

Abstract

Introduction

Prostate cancer is a leading cause of cancer-related mortality in men worldwide, and the treatment of metastatic castration-resistant prostate cancer (mCRPC) remains a major clinical challenge. CD24, a glycosylated cell surface protein, plays a critical role in tumor progression and immune evasion. This review focuses on the role of CD24 in prostate cancer pathogenesis, particularly its interaction with mutant p53, and explores potential therapeutic implications.

Methods

Through a systematic search of the PubMed, Web of Science, and Embase databases (2015–2025), using the following structured search terms: (CD24 OR “CD24 antigen”) AND (“prostate cancer” OR “prostatic neoplasms”) AND (“mutant p53” OR “TP53 mutation”) AND (“targeted therapy” OR immunotherapy), relevant studies were identified and screened according to PRISMA guidelines.

Results

CD24 overexpression was significantly associated with high Gleason scores, metastasis, and poor prognosis. Mechanistically, CD24 promotes tumor progression by destabilizing p53 through the disruption of ARF-NPM interactions and by synergizing with mutant p53. Preclinical studies indicate that therapies targeting CD24, such as CAR-T cells and nanoparticle-based drug delivery systems, demonstrate potent anti-tumor effects.

Discussion

The CD24–p53 axis is amplified in mCRPC and interacts with androgen receptor signaling, while tumor microenvironment factors further enhance treatment resistance.

Conclusion

CD24 and mutant p53 represent promising therapeutic targets in metastatic castration-resistant prostate cancer (mCRPC). Translating these targeting strategies into clinical practice may help overcome current therapeutic challenges and improve patient outcomes.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206405420251117053720
2026-01-05
2026-03-03

  • From This Site

    /content/journals/acamc/10.2174/0118715206405420251117053720
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Culp M.B. Soerjomataram I. Efstathiou J.A. Bray F. Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur. Urol. 2020 77 1 38 52 10.1016/j.eururo.2019.08.005 31493960
    [Google Scholar]
  2. Zhang J.Y. Zhao L.J. Wang Y.T. Synthesis and clinical application of small-molecule drugs approved to treat prostatic cancer. Eur. J. Med. Chem. 2023 262 115925 10.1016/j.ejmech.2023.115925 37948954
    [Google Scholar]
  3. Fallara G. Belladelli F. Robesti D. Raggi D. Nocera L. Marandino L. Galsky M.D. Montorsi F. Malavaud B. Ploussard G. Necchi A. Martini A. Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 2022 179 103801 10.1016/j.critrevonc.2022.103801 36031173
    [Google Scholar]
  4. Rahman M. Akter K. Ahmed K.R. Fahim M.M.H. Aktary N. Park M.N. Shin S.W. Kim B. Synergistic strategies for castration-resistant prostate cancer: Targeting AR-V7, exploring natural compounds, and optimizing FDA-approved therapies. Cancers 2024 16 16 2777 10.3390/cancers16162777 39199550
    [Google Scholar]
  5. Li Y. Li F. Han S. Ning J. Su P. Liu J. Qu L. Huang S. Wang S. Li X. Li X. Performance of 18F-DCFPyL PET/CT in Primary Prostate cancer diagnosis, gleason grading and D’amico classification: A radiomics-based study. Phenomics 2023 3 6 576 585 10.1007/s43657‑023‑00108‑y 38223686
    [Google Scholar]
  6. Younes M. Loubnane G. Sleiman C. Rizk S. Tocotrienol isoforms: The molecular mechanisms underlying their effects in cancer therapy and their implementation in clinical trials. J. Integr. Med. 2024 22 1 1 11 10.1016/j.joim.2024.01.002 38336507
    [Google Scholar]
  7. Yang Y. Zhu G. Yang L. Yang Y. Targeting CD24 as a novel immunotherapy for solid cancers. Cell Commun. Signal. 2023 21 1 312 10.1186/s12964‑023‑01315‑w 37919766
    [Google Scholar]
  8. Constantin M. Chifiriuc M.C. Mihaescu G. Corcionivoschi N. Burlibasa L. Bleotu C. Tudorache S. Mitache M.M. Filip R. Munteanu S.G. Gradisteanu Pircalabioru G. Microbiome and cancer: From mechanistic implications in disease progression and treatment to development of novel antitumoral strategies. Front. Immunol. 2024 15 1373504 10.3389/fimmu.2024.1373504 38715617
    [Google Scholar]
  9. Altevogt P. Sammar M. Hüser L. Kristiansen G. Novel insights into the function of CD24: A driving force in cancer. Int. J. Cancer 2021 148 3 546 559 10.1002/ijc.33249 32790899
    [Google Scholar]
  10. Tan Y. Zhao M. Xiang B. Chang C. Lu Q. CD24: From a hematopoietic differentiation antigen to a genetic risk factor for multiple autoimmune diseases. Clin. Rev. Allergy Immunol. 2016 50 1 70 83 10.1007/s12016‑015‑8470‑2 25666875
    [Google Scholar]
  11. Barkal A.A. Brewer R.E. Markovic M. Kowarsky M. Barkal S.A. Zaro B.W. Krishnan V. Hatakeyama J. Dorigo O. Barkal L.J. Weissman I.L. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 2019 572 7769 392 396 10.1038/s41586‑019‑1456‑0 31367043
    [Google Scholar]
  12. Li X. Tian W. Jiang Z. Song Y. Leng X. Yu J. Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions. Cancer Immunol. Immunother. 2024 73 2 31 10.1007/s00262‑023‑03606‑0 38279998
    [Google Scholar]
  13. Zhang Y. Thayele Purayil H. Black J.B. Fetto F. Lynch L.D. Masannat J.N. Daaka Y. Prostaglandin E2 receptor 4 mediates renal cell carcinoma intravasation and metastasis. Cancer Lett. 2017 391 50 58 10.1016/j.canlet.2017.01.007 28104442
    [Google Scholar]
  14. Yeini E. Satchi-Fainaro R. The role of P-selectin in cancerassociated thrombosis and beyond. Thromb Res., 213, S22- S28. Suppl. 1 10.1016/j.thromres.2021.12.027 36210556 2022
    [Google Scholar]
  15. Wang Y-H. Wu S-Q. Su H. Zhao X.K. Role of tumor-associated immune cells in prostate cancer: Angel or devil? Asian J. Androl. 2019 21 5 433 437 10.4103/aja.aja_47_19 31134920
    [Google Scholar]
  16. Li W. Ma H. Zhang J. Zhu L. Wang C. Yang Y. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci. Rep. 2017 7 1 13856 10.1038/s41598‑017‑14364‑2 29062075
    [Google Scholar]
  17. Mestermann K. Garitano-Trojaola A. Hudecek M. Accelerating CAR-T cell therapies with small-molecule inhibitors. BioDrugs 2025 39 1 33 51 10.1007/s40259‑024‑00688‑9 39589646
    [Google Scholar]
  18. Zhou L. Feng Y. Hong R. Wei G. Zhang M. Chang A.H. Huang H. Hu Y. Integrating genomic features for prognosis in Chinese patients with B-cell lymphoma following chimeric antigen receptor T-cell therapy. Sci. China Life Sci. 2025 68 6 1703 1713 10.1007/s11427‑024‑2783‑2 40189492
    [Google Scholar]
  19. Chen W. Hu Z. Guo Z. Targeting CD24 in cancer immunotherapy. Biomedicines 2023 11 12 3159 10.3390/biomedicines11123159 38137380
    [Google Scholar]
  20. Yang P. Yu F. Yao Z. Ding X. Xu H. Zhang J. CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer. Cancer Immunol. Immunother. 2023 72 10 3191 3202 10.1007/s00262‑023‑03491‑7 37418008
    [Google Scholar]
  21. Gupta A. Shah K. Oza M.J. Behl T. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment. Biomed. Pharmacother. 2019 109 484 492 10.1016/j.biopha.2018.10.155 30551517
    [Google Scholar]
  22. Blagih J. Buck M.D. Vousden K.H. p53, cancer and the immune response. J. Cell Sci. 2020 133 5 jcs237453 10.1242/jcs.237453 32144194
    [Google Scholar]
  23. Liu W. Zhang Y. Wei S. Bae S. Yang W.H. Smith G.J. Mohler J.L. Fontham E.T.H. Bensen J.T. Sonpavde G.P. Chen G.Y. Liu R. Wang L.A. CD24‐p53 axis contributes to African American prostate cancer disparities. Prostate 2020 80 8 609 618 10.1002/pros.23973 32168400
    [Google Scholar]
  24. Ayre D.C. Pallegar N.K. Fairbridge N.A. Canuti M. Lang A.S. Christian S.L. Analysis of the structure, evolution, and expression of CD24, an important regulator of cell fate. Gene 2016 590 2 324 337 10.1016/j.gene.2016.05.038 27259665
    [Google Scholar]
  25. Panagiotou E. Syrigos N.K. Charpidou A. Kotteas E. Vathiotis I.A. CD24: A novel target for cancer immunotherapy. J. Pers. Med. 2022 12 8 1235 10.3390/jpm12081235 36013184
    [Google Scholar]
  26. Fang X. Zheng P. Tang J. Liu Y. CD24: From A to Z. Cell. Mol. Immunol. 2010 7 2 100 103 10.1038/cmi.2009.119 20154703
    [Google Scholar]
  27. AbuSamra D.B. Al-Kilani A. Hamdan S.M. Sakashita K. Gadhoum S.Z. Merzaban J.S. Quantitative characterization of E-selectin interaction with native CD44 and P-selectin Glycoprotein Ligand-1 (PSGL-1) using a real time immunoprecipitation-based binding assay. J. Biol. Chem. 2015 290 35 21213 21230 10.1074/jbc.M114.629451 26124272
    [Google Scholar]
  28. Aigner S. Sthoeger Z.M. Fogel M. Weber E. Zarn J. Ruppert M. Zeller Y. Vestweber D. Stahel R. Sammar M. Altevogt P. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997 89 9 3385 3395 10.1182/blood.V89.9.3385 9129046
    [Google Scholar]
  29. Liu Y. Zheng P. CD24-Siglec interactions in inflammatory diseases. Front. Immunol. 2023 14 1174789 10.3389/fimmu.2023.1174789 37228622
    [Google Scholar]
  30. Chen G.Y. Tang J. Zheng P. Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009 323 5922 1722 1725 10.1126/science.1168988 19264983
    [Google Scholar]
  31. Liu Y. Chen G.Y. Zheng P. CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns. Trends Immunol. 2009 30 12 557 561 10.1016/j.it.2009.09.006 19786366
    [Google Scholar]
  32. Huang S. Zhang X. Wei Y. Xiao Y. Checkpoint CD24 function on tumor and immunotherapy. Front. Immunol. 2024 15 1367959 10.3389/fimmu.2024.1367959 38487533
    [Google Scholar]
  33. Li L. Chen J. Ge C. Zhao F. Chen T. Tian H. Li J. Li H. CD24 isoform a promotes cell proliferation, migration and invasion and is downregulated by EGR1 in hepatocellular carcinoma. OncoTargets Ther. 2019 12 1705 1716 10.2147/OTT.S196506 30881025
    [Google Scholar]
  34. Hong P. Xu T. Xu J. Chen W. Hu H. Chen J. Li L. Zheng C. Li B. Liu J. Dai W. Li E. Zhang F. Xu W. CD24 promotes metastasis and chemoresistance by directly targeting Arf6-ERK pathway in esophageal squamous cell carcinoma. Cancer Lett. 2024 594 216994 10.1016/j.canlet.2024.216994 38801885
    [Google Scholar]
  35. Costa C.D. Justo A.A. Kobayashi P.E. Story M.M. Palmieri C. Laufer Amorim R. Fonseca-Alves C.E. Characterization of OCT3/4, Nestin, NANOG, CD44 and CD24 as stem cell markers in canine prostate cancer. Int. J. Biochem. Cell Biol. 2019 108 21 28 10.1016/j.biocel.2019.01.002 30633985
    [Google Scholar]
  36. Leis-Filho A.F. Lainetti P.F. Franzoni M.S. Palmieri C. Kobayshi P.E. Laufer-Amorim R. Fonseca-Alves C.E. A comparative in silico analysis of CD24’s prognostic value in human and canine prostate cancer. J. Pers. Med. 2021 11 3 232 10.3390/jpm11030232 33806857
    [Google Scholar]
  37. Athanassiadou P. Grapsa D. Gonidi M. Athanassiadou A.M. Tsipis A. Patsouris E. CD24 expression has a prognostic impact in breast carcinoma. Pathol. Res. Pract. 2009 205 8 524 533 10.1016/j.prp.2009.01.008 19243896
    [Google Scholar]
  38. Sano A. Kato H. Sakurai S. Sakai M. Tanaka N. Inose T. Saito K. Sohda M. Nakajima M. Nakajima T. Kuwano H. CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma. Ann. Surg. Oncol. 2009 16 2 506 514 10.1245/s10434‑008‑0252‑0 19050962
    [Google Scholar]
  39. Huh S.J. Clement K. Jee D. Merlini A. Choudhury S. Maruyama R. Yoo R. Chytil A. Boyle P. Ran F.A. Moses H.L. Barcellos-Hoff M.H. Jackson-Grusby L. Meissner A. Polyak K. Age- and pregnancy-associated DNA methylation changes in mammary epithelial cells. Stem Cell Reports 2015 4 2 297 311 10.1016/j.stemcr.2014.12.009 25619437
    [Google Scholar]
  40. Tolkach Y. Zarbl R. Bauer S. Ritter M. Ellinger J. Hauser S. Hüser L. Klauck S.M. Altevogt P. Sültmann H. Dietrich D. Kristiansen G. DNA promoter methylation and ERG regulate the expression of CD24 in prostate cancer. Am. J. Pathol. 2021 191 4 618 630 10.1016/j.ajpath.2020.12.014 33485866
    [Google Scholar]
  41. Zhang Y. Li B. Zhang X. Sonpavde G.P. Jiao K. Zhang A. Zhang G. Sun M. Chu C. Li F. Wang L. Cui R. Liu R. CD24 is a genetic modifier for risk and progression of prostate cancer. Mol. Carcinog. 2017 56 2 641 650 10.1002/mc.22522 27377469
    [Google Scholar]
  42. Kachikwu E.L. Iwamoto K.S. Liao Y.P. DeMarco J.J. Agazaryan N. Economou J.S. McBride W.H. Schaue D. Radiation enhances regulatory T cell representation. Int. J. Radiat. Oncol. Biol. Phys. 2011 81 4 1128 1135 10.1016/j.ijrobp.2010.09.034 21093169
    [Google Scholar]
  43. Cremers N. Neeb A. Uhle T. Dimmler A. Rothley M. Allgayer H. Fodde R. Sleeman J.P. Thiele W. CD24 Is Not Required for Tumor Initiation and Growth in Murine Breast and Prostate Cancer Models. PLoS One 2016 11 3 e0151468 10.1371/journal.pone.0151468 26978528
    [Google Scholar]
  44. Söhngen C. Thomas D.J. Skowron M.A. Bremmer F. Eckstein M. Stefanski A. Driessen M.D. Wakileh G.A. Stühler K. Altevogt P. Theodorescu D. Klapdor R. Schambach A. Nettersheim D. CD24 targeting with NK‐CAR immunotherapy in testis, prostate, renal and (luminal‐type) bladder cancer and identification of direct CD24 interaction partners. FEBS J. 2023 290 20 4864 4876 10.1111/febs.16880 37254618
    [Google Scholar]
  45. Sajedifar M. Jafarabadi A. Jalali Nadoushan M. Differences in CD24 Expression Between Prostate Adenocarcinoma and Benign Prostatic Hyperplasia: A Cross-sectional Study. Iran. J. Pathol. 2024 19 3 306 310 10.30699/ijp.2024.2021959.3251 39687458
    [Google Scholar]
  46. Weng C.C. Ding P.Y. Liu Y.H. Hawse J.R. Subramaniam M. Wu C.C. Lin Y.C. Chen C.Y. Hung W.C. Cheng K.H. Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis. Oncogene 2019 38 12 2005 2019 10.1038/s41388‑018‑0575‑7 30467381
    [Google Scholar]
  47. Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021 71 3 209 249 10.3322/caac.21660 33538338
    [Google Scholar]
  48. Saito S. Ando K. Sakamoto S. Xu M. Yamada Y. Rii J. Kanaoka S. Wei J. Zhao X. Pae S. Kanesaka M. Goto Y. Sazuka T. Imamura Y. Reien Y. Hamaguchi-Suzuki N. Saito S. Hirayama Y. Hashimoto H. Kanai Y. Ichikawa T. Anzai N. The LAT1 inhibitor JPH203 suppresses the growth of castration‐resistant prostate cancer through a CD24 ‐mediated mechanism. Cancer Sci. 2024 115 7 2461 2472 10.1111/cas.16191 38655663
    [Google Scholar]
  49. Agarwal N. Dancik G.M. Goodspeed A. Costello J.C. Owens C. Duex J.E. Theodorescu D. GON4L Drives Cancer Growth through a YY1–Androgen Receptor–CD24 Axis. Cancer Res. 2016 76 17 5175 5185 10.1158/0008‑5472.CAN‑16‑1099 27312530
    [Google Scholar]
  50. Petkova N. Hennenlotter J. Sobiesiak M. Todenhöfer T. Scharpf M. Stenzl A. Bühring H.J. Schwentner C. Surface CD24 distinguishes between low differentiated and transit‐amplifying cells in the basal layer of human prostate. Prostate 2013 73 14 1576 1590 10.1002/pros.22708 23836489
    [Google Scholar]
  51. Marei H.E. Althani A. Afifi N. Hasan A. Caceci T. Pozzoli G. Morrione A. Giordano A. Cenciarelli C. p53 signaling in cancer progression and therapy. Cancer Cell Int. 2021 21 1 703 10.1186/s12935‑021‑02396‑8 34952583
    [Google Scholar]
  52. Kumari S. Sharma V. Tiwari R. Maurya J.P. Subudhi B.B. Senapati D. Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities. Eur. J. Pharmacol. 2022 919 174807 10.1016/j.ejphar.2022.174807 35151649
    [Google Scholar]
  53. Teroerde M. Nientiedt C. Duensing A. Hohenfellner M. Stenzinger A. Duensing S. Revisiting the role of p53 in prostate cancer. In: Prostate Cancer; Exon Publications: Brisban 2021 10.36255/exoncitations.prostatecancer.p53.2021
    [Google Scholar]
  54. Ding D. Blee A.M. Zhang J. Pan Y. Becker N.A. Maher L.J. Jimenez R. Wang L. Huang H. Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis. Nat. Commun. 2023 14 1 4671 10.1038/s41467‑023‑40352‑4 37537199
    [Google Scholar]
  55. McCann J.J. Vasilevskaya I.A. McNair C. Gallagher P. Neupane N.P. de Leeuw R. Shafi A.A. Dylgjeri E. Mandigo A.C. Schiewer M.J. Knudsen K.E. Mutant p53 elicits context-dependent pro-tumorigenic phenotypes. Oncogene 2022 41 3 444 458 10.1038/s41388‑021‑01903‑5 34773073
    [Google Scholar]
  56. Valentino E. Bellazzo A. Di Minin G. Sicari D. Apollonio M. Scognamiglio G. Di Bonito M. Botti G. Del Sal G. Collavin L. Mutant p53 potentiates the oncogenic effects of insulin by inhibiting the tumor suppressor DAB2IP. Proc. Natl. Acad. Sci. USA 2017 114 29 7623 7628 10.1073/pnas.1700996114 28667123
    [Google Scholar]
  57. Nowak D.G. Cho H. Herzka T. Watrud K. DeMarco D.V. Wang V.M.Y. Senturk S. Fellmann C. Ding D. Beinortas T. Kleinman D. Chen M. Sordella R. Wilkinson J.E. Castillo-Martin M. Cordon-Cardo C. Robinson B.D. Trotman L.C. MYC Drives Pten/Trp53 -Deficient proliferation and metastasis due to IL6 secretion and AKT suppression via PHLPP2. Cancer Discov. 2015 5 6 636 651 10.1158/2159‑8290.CD‑14‑1113 25829425
    [Google Scholar]
  58. Chaudagar K. Hieromnimon H.M. Khurana R. Labadie B. Hirz T. Mei S. Hasan R. Shafran J. Kelley A. Apostolov E. Al-Eryani G. Harvey K. Rameshbabu S. Loyd M. Bynoe K. Drovetsky C. Solanki A. Markiewicz E. Zamora M. Fan X. Schürer S. Swarbrick A. Sykes D.B. Patnaik A. Reversal of lactate and PD-1–mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer. Clin. Cancer Res. 2023 29 10 1952 1968 10.1158/1078‑0432.CCR‑22‑3350 36862086
    [Google Scholar]
  59. Wang Z. Chao Z. Wang Q. Zou F. Song T. Xu L. Ning J. Cheng F. EXO1/P53/SREBP1 axis-regulated lipid metabolism promotes prostate cancer progression. J. Transl. Med. 2024 22 1 104 10.1186/s12967‑023‑04822‑z 38279172
    [Google Scholar]
  60. Ge Q. Wang C. Ruan Y. Chen Z. Liu J. Ye Z. Overexpression of p53 activated by small activating RNA suppresses the growth of human prostate cancer cells. OncoTargets Ther. 2016 9 231 241 10.2147/ott.S96710 26811691
    [Google Scholar]
  61. Zhao Y. Ding L. Wang D. Ye Z. He Y. Ma L. Zhu R. Pan Y. Wu Q. Pang K. Hou X. Weroha S.J. Han C. Coleman R. Coleman I. Karnes R.J. Zhang J. Nelson P.S. Wang L. Huang H. EZH 2 cooperates with gain‐of‐function p53 mutants to promote cancer growth and metastasis. EMBO J. 2019 38 5 e99599 10.15252/embj.201899599 30723117
    [Google Scholar]
  62. Chaudagar K. Hieromnimon H.M. Kelley A. Labadie B. Shafran J. Rameshbabu S. Drovetsky C. Bynoe K. Solanki A. Markiewicz E. Fan X. Loda M. Patnaik A. Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient Aggressive-variant prostate cancer via macrophage phagocytosis. Clin. Cancer Res. 2023 29 23 4930 4940 10.1158/1078‑0432.CCR‑23‑1441 37721526
    [Google Scholar]
  63. Li D. Zhan Y. Wang N. Tang F. Lee C.J. Bayshtok G. Moore A.R. Wong E.W.P. Pachai M.R. Xie Y. Sher J. Zhao J.L. Khudoynazarova M. Gopalan A. Chan J. Khurana E. Shepherd P. Navone N.M. Chi P. Chen Y. ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer. Sci. Adv. 2023 9 14 eadc9446 10.1126/sciadv.adc9446 37018402
    [Google Scholar]
  64. Li J. Li Y. Chen L. Yu B. Xue Y. Guo R. Su J. Liu Y. Sun L. p53/PGC 1α mediated mitochondrial dysfunction promotes PC3 prostate cancer cell apoptosis. Mol. Med. Rep. 2020 22 1 155 164 10.3892/mmr.2020.11121 32377739
    [Google Scholar]
  65. Ray P. Shukla S. Zhang Y. Donahue K.L. Nancarrow D.J. Kasturirangan S. Shankar S. Cuneo K. Thomas D. Gadgeel S.M. Lawrence T.S. Pasca di Magliano M. Ray D. SMURF2 facilitates GAP17 Isoform 1 membrane displacement to promote mutant p53–KRAS oncogenic synergy. Mol. Cancer Res. 2025 23 6 530 541 10.1158/1541‑7786.MCR‑24‑0701 39976545
    [Google Scholar]
  66. Wang L. Liu R. Ye P. Wong C. Chen G.Y. Zhou P. Sakabe K. Zheng X. Wu W. Zhang P. Jiang T. Bassetti M.F. Jube S. Sun Y. Zhang Y. Zheng P. Liu Y. Intracellular CD24 disrupts the ARF–NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation. Nat. Commun. 2015 6 1 5909 10.1038/ncomms6909 25600590
    [Google Scholar]
  67. Zhang W. Yi B. Wang C. Chen D. Bae S. Wei S. Guo R.J. Lu C. Nguyen L.L.H. Yang W.H. Lillard J.W. Zhang X. Wang L. Liu R. Silencing of CD24 enhances the PRIMA-1–Induced restoration of mutant p53 in prostate cancer cells. Clin. Cancer Res. 2016 22 10 2545 2554 10.1158/1078‑0432.CCR‑15‑1927 26712693
    [Google Scholar]
  68. Li D. Hu M. Liu Y. Ye P. Du P. Li C.S. Cheng L. Liu P. Jiang J. Su L. Wang S. Zheng P. Liu Y. CD24–p53 axis suppresses diethylnitrosamine-induced hepatocellular carcinogenesis by sustaining intrahepatic macrophages. Cell Discov. 2018 4 1 6 10.1038/s41421‑017‑0007‑9 29423273
    [Google Scholar]
  69. Huang L.R. Hsu H.C. Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res. 1995 55 20 4717 4721 7553654
    [Google Scholar]
  70. Wu Z. Thierry K. Bachy S. Zhang X. Gamradt P. Hernandez-Vargas H. Mikaelian I. Tonon L. Pommier R. Zhao Y. Bertolino P. Hennino A. Pericyte stem cells induce Ly6G + cell accumulation and immunotherapy resistance in pancreatic cancer. EMBO Rep. 2023 24 4 e56524 10.15252/embr.202256524 36802267
    [Google Scholar]
  71. Song B. Lee J.M. Park Y.J. Kim I.K. Kim B.S. Shin K.S. Jeon I. Koh C.H. Bae E.A. Seo H. Byun Y. Kang C.Y. Differentiation of c‐Kit + CD24 + natural killer cells into myeloid cells in a GATA‐2‐dependent manner. FASEB J. 2020 34 3 4462 4481 10.1096/fj.201902662R 31989715
    [Google Scholar]
  72. Li X. Jin C. Chen Q. Zheng X. Xie D. Wu Q. Wang L. Bai S. Zhang H. Bai L. Identification of liver-specific CD24+ invariant NK T cells with low granzyme B production and high proliferative capacity. J. Leukoc. Biol. 2022 111 6 1199 1210 10.1002/JLB.1A0621‑309R 34730251
    [Google Scholar]
  73. van Bruggen J.A.C. Peters F.S. Mes M. Rietveld J.M. Cerretani E. Cretenet G. van Kampen R. Jongejan A. Moerland P.D. Melenhorst J.J. van der Windt G.J.W. Eldering E. Kater A.P. T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells. Blood Adv. 2024 8 17 4633 4646 10.1182/bloodadvances.2023011934 39042920
    [Google Scholar]
  74. Huang Y. Yang X. Li J. Zhou W. Wang F. Li J. Zhang Y. Yan F. Gao H. Gu X. Luo S. Yang Y. Liu M. Liang X. Jiang L. Fu M. Su J. Wei Y. Wang W. CD24-targeted CAR-T cells mediated long-term antitumor efficacy through activation of endogenous tumor immune responses. Mol. Cancer Ther. 2025 24 7 1075 1087 10.1158/1535‑7163.MCT‑24‑0597 40105191
    [Google Scholar]
  75. Li W. Zhang B. Cao W. Zhang W. Li T. Liu L. Xu L. Gao F. Wang Y. Wang F. Xing H. Jiang Z. Shi J. Bian Z. Song Y. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing. Exp. Hematol. Oncol. 2023 12 1 44 10.1186/s40164‑023‑00402‑5 37158921
    [Google Scholar]
  76. Sun F. Cheng Y. Wanchai V. Guo W. Mery D. Xu H. Gai D. Siegel E. Bailey C. Ashby C. Al Hadidi S. Schinke C. Thanendrarajan S. Ma Y. Yi Q. Orlowski R.Z. Zangari M. van Rhee F. Janz S. Bishop G. Tricot G. Shaughnessy J.D. Zhan F. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat. Commun. 2024 15 1 615 10.1038/s41467‑024‑44873‑4 38242888
    [Google Scholar]
  77. DeSelm C.J. Tano Z.E. Varghese A.M. Adusumilli P.S. CAR T‐cell therapy for pancreatic cancer. J. Surg. Oncol. 2017 116 1 63 74 10.1002/jso.24627 28346697
    [Google Scholar]
  78. Shen W. Shi P. Dong Q. Zhou X. Chen C. Sui X. Tian W. Zhu X. Wang X. Jin S. Wu Y. Chen G. Qiu L. Zhai W. Gao Y. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy. J. Immunother. Cancer 2023 11 6 e007068 10.1136/jitc‑2023‑007068 37344099
    [Google Scholar]
  79. Wang K. Yu A. Liu K. Feng C. Hou Y. Chen J. Ma S. Huang L. Dai X. Nano‐LYTACs for degradation of membrane proteins and inhibition of CD24/Siglec‐10 signaling pathway. Adv. Sci. (Weinh.) 2023 10 13 2300288 10.1002/advs.202300288 36866919
    [Google Scholar]
  80. Zhu J. He J. Liu Y. Simeone D.M. Lubman D.M. Identification of glycoprotein markers for pancreatic cancer CD24+CD44+ stem-like cells using nano-LC-MS/MS and tissue microarray. J. Proteome Res. 2012 11 4 2272 2281 10.1021/pr201059g 22335271
    [Google Scholar]
  81. Bharali D.J. Sudha T. Cui H. Mian B.M. Mousa S.A. Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer. Nanomedicine 2017 13 1 263 273 10.1016/j.nano.2016.08.017 27565690
    [Google Scholar]
  82. Jaworska D. Szliszka E. Targeting apoptotic activity against prostate cancer stem cells. Int. J. Mol. Sci. 2017 18 8 1648 10.3390/ijms18081648 28758908
    [Google Scholar]
  83. Lehmann S. Bykov V.J.N. Ali D. Andrén O. Cherif H. Tidefelt U. Uggla B. Yachnin J. Juliusson G. Moshfegh A. Paul C. Wiman K.G. Andersson P.O. Targeting p53 in vivo: A first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J. Clin. Oncol. 2012 30 29 3633 3639 10.1200/JCO.2011.40.7783 22965953
    [Google Scholar]
  84. Zhang Y. Xu L. Chang Y. Li Y. Butler W. Jin E. Wang A. Tao Y. Chen X. Liang C. Huang J. Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC. Prostate Cancer Prostatic Dis. 2020 23 1 160 171 10.1038/s41391‑019‑0172‑z 31471556
    [Google Scholar]
  85. Natarajan U. Venkatesan T. Radhakrishnan V. Samuel S. Rasappan P. Rathinavelu A. Cell cycle arrest and cytotoxic effects of SAHA and RG7388 mediated through p21WAF1/CIP1 and p27KIP1 in cancer cells. Medicina (Kaunas) 2019 55 2 30 10.3390/medicina55020030 30700046
    [Google Scholar]
  86. Chang Y.S. Graves B. Guerlavais V. Tovar C. Packman K. To K.H. Olson K.A. Kesavan K. Gangurde P. Mukherjee A. Baker T. Darlak K. Elkin C. Filipovic Z. Qureshi F.Z. Cai H. Berry P. Feyfant E. Shi X.E. Horstick J. Annis D.A. Manning A.M. Fotouhi N. Nash H. Vassilev L.T. Sawyer T.K. Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc. Natl. Acad. Sci. USA 2013 110 36 E3445 E3454 10.1073/pnas.1303002110 23946421
    [Google Scholar]
  87. Morris M.J. Castellano D. Herrmann K. de Bono J.S. Shore N.D. Chi K.N. Crosby M. Piulats J.M. Fléchon A. Wei X.X. Mahammedi H. Roubaud G. Študentová H. Nagarajah J. Mellado B. Montesa-Pino Á. Kpamegan E. Ghebremariam S. Kreisl T.N. Wilke C. Lehnhoff K. Sartor O. Fizazi K. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3, randomised, controlled trial. Lancet 2024 404 10459 1227 1239 10.1016/S0140‑6736(24)01653‑2 39293462
    [Google Scholar]
  88. Murthy V. Voter A. F. Nguyen K. Allen-Auerbach M. Chen L. Caputo S. Ledet E. Akerele A. Moradi Tuchayi A. Lawhn-Heath C. Wang T. Carducci M. A. Pomper M. G. Paller C. J. Czernin J. Solnes L. B. Hope T. A. Sartor O. Calais J. Gafita A. 2024
  89. Bossi A. Foulon S. Maldonado X. Sargos P. MacDermott R. Kelly P. Fléchon A. Tombal B. Supiot S. Berthold D. Ronchin P. Kacso G. Salem N. Calabro F. Berdah J.F. Hasbini A. Silva M. Boustani J. Ribault H. Fizazi K. Bossi A. Foulon S. Maldonado X. Sargos P. MacDermott R. Kelly P. Fléchon A. Tombal B. Supiot S. Berthold D. Ronchin P. Kacso G. Salem N. Calabro F. Berdah J-F. Hasbini A. Silva M. Boustani J. Ribault H. Fizazi K. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 2024 404 10467 2065 2076 10.1016/S0140‑6736(24)01865‑8 39580202
    [Google Scholar]
  90. Emmett L. Subramaniam S. Crumbaker M. Joshua A.M. Sandhu S. Nguyen A. Weickhardt A. Lee S.T. Ng S. Francis R.J. Goh J.C. Pattison D.A. Tan T.H. Kirkwood I.D. Gedye C. Rutherford N.K. Kumar A.S.R. Pook D. Ramdave S. Nadebaum D.P. Voskoboynik M. Redfern A.D. Macdonald W. Krieger L. Schembri G. Chua W. Lin P. Horvath L. Bastick P. Butler P. Zhang A.Y. McJannett M. Thomas H. Langford A. Hofman M.S. Martin A.J. Davis I.D. Stockler M.R. Emmett L. Subramaniam S. Crumbaker M. Joshua A.M. Sandhu S. Nguyen A. Weickhardt A. Lee S-T. Ng S. Francis R.J. Goh J.C. Pattison D.A. Tan T.H. Kirkwood I.D. Gedye C. Rutherford N.K. Ravi Kumar A.S. Pook D. Ramdave S. Nadebaum D.P. Voskoboynik M. Redfern A.D. Macdonald W. Krieger L. Schembri G. Chua W. Lin P. Horvath L. Bastick P. Butler P. Zhang A.Y. McJannett M. Thomas H. Langford A. Hofman M.S. Martin A.J. Davis I.D. Stockler M.R. Zebic D. Mak B. Tankard N. Rana N. Cusick T. Thompson J. Oakes S. Niu C. Thein T. Ford K. Ristevski N. Yip S. Bills M. Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): Secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025 26 3 291 299 10.1016/S1470‑2045(25)00009‑9 39956124
    [Google Scholar]
  91. Petrylak D.P. Ratta R. Matsubara N. Korbenfeld E. Gafanov R. Mourey L. Todenhöfer T. Gurney H. Kramer G. Bergman A.M. Zalewski P. De Santis M. Armstrong A.J. Gerritsen W. Pachynski R. Byun S.S. Retz M. Levesque E. McDermott R. Bracarda S. Manneh R. Levartovsky M. Li X.T. Schloss C. Poehlein C.H. Fizazi K. Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: The randomized, double-blind, phase III KEYNOTE-921 Trial. J. Clin. Oncol. 2025 43 14 1638 1649 10.1200/JCO‑24‑01283 40043230
    [Google Scholar]
/content/journals/acamc/10.2174/0118715206405420251117053720
Loading
CD24 and Mutant p53: Emerging Therapeutic Targets in Prostate Cancer Progression
Bentham Science Publishers ; https://doi.org/10.2174/0118715206405420251117053720
/content/journals/acamc/10.2174/0118715206405420251117053720
/content/journals/acamc/10.2174/0118715206405420251117053720
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: mutant p53 ; targeted therapy ; CD24 ; tumour micro-enviroment ; immunotherapy ; prostate cancer

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test